farapulse boston scientific news - Search News

Boston Scientific Earnings, Sales Top Q3 Views

Seeking Alpha on MSN · 1d

Boston Sci stock falls 4% amid FARAPULSE study update

Boston Scientific (NYSE:BSX) shares were down 5% in morning trading Wednesday following news that the company has paused a study for its new FARAPULSE Pulse Field Ablation system due to unforeseen complications.

MarketWatch on MSN · 2d

Boston Scientific stock climbs on Q3 sales and earnings beat

Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products company reported better-than-expected profit and sales in its third-quarter results, and gave robust earnings guidance.

Houston Chronicle · 2d

Boston Scientific: Q3 Earnings Snapshot

The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of 58 cents per share. The medical device manufacturer posted revenue of $4.21 billion in the period, also exceeding Street forecasts.

1d

Boston Scientific lifts sales outlook, notes key approval of AFib device with Minnesota ties

The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...

1d

Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm

In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...

FierceBiotech1d

Boston Scientific posts 177% EP growth, pauses Farapulse study in first-line afib

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...

2d

Boston Scientific Q3 Earnings Preview

In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the ...

1d

Boston Scientific Faces Trial Setback, But This Game-Changing Growth Surge Could Ignite the Stock

Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...

Boston Scientific still expects Axonics deal to close this year, posts Street-beating Q3

Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...

GlobalData on MSN3d

FDA greenlights add-ons for Boston Scientific’s Farapulse field ablation system

The Farawave NAV ablation catheter and the Faraview software are used with the Farapulse field ablation system to provide ...

Boston Scientific boosts PFA expectations, citing rapid Farapulse adoption

Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...

Boston Scientific wins FDA nods for nav-enabled Farapulse catheter, software

Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...

20h

Boston Scientific price target raised to $110 from $100 at Mizuho

Mizuho raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps an Outperform rating on the shares post the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results